ArticleBMC geriatrics2026
Association between neurofilament light chain, glial fibrillary acidic protein, and sarcopenia in older Indian adults: evidence from LASI-DAD.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia, the age-related loss of muscle mass and strength, is a leading cause of disability and frailty in older adults. Though primarily seen as a musculoskeletal condition, emerging evidence suggests a role for neurodegenerative mechanisms such as axonal loss and neuroinflammation. Circulating biomarkers like glial fibrillary acidic protein (GFAP), reflecting astrocyte activation, and neurofilament light chain (NfL), indicating axonal injury, may signal subclinical neurological dysfunction. This study examined associations between plasma GFAP and NfL levels and the presence and severity of sarcopenia in older Indian adults using data from the nationally representative Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (LASI-DAD) cohort.
methodsWe used data from the Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (LASI-DAD), a nationally representative sample of older adults aged ≥ 60 years. Sarcopenia was classified using Asian Working Group for Sarcopenia (AWGS) 2019 criteria based on handgrip strength, gait speed, and calf circumference, and categorized into no sarcopenia, sarcopenia, and severe sarcopenia. Plasma levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were quantified using Simoa® HDX platform.
resultsWe analyzed 1,429 community-dwelling older adults; 53.1% had sarcopenia and 38.6% had severe sarcopenia. Median plasma GFAP levels increased from 99.6 pg/mL (IQR: 70.2–140.9) in those without sarcopenia to 122.4 pg/mL (IQR: 84.0–181.6) in sarcopenia and 158.1 pg/mL (IQR: 101.4–228.4) in severe sarcopenia (p < 0.001). Similarly, median NfL levels were 20.5 pg/mL (IQR: 15.8–29.4), 29.1 pg/mL (IQR: 19.8–44.6), and 37.6 pg/mL (IQR: 25.0–59.2), respectively (p < 0.001). In fully adjusted models, higher GFAP levels were associated with sarcopenia (RRR: 1.23; 95% CI: 1.04–1.45; p = 0.014) and severe sarcopenia (RRR: 1.48; 95% CI: 1.19–1.83; p < 0.001). NfL was associated with sarcopenia (RRR: 1.37; 95% CI: 1.16–1.61; p < 0.001) and severe sarcopenia (RRR: 2.01; 95% CI: 1.56–2.58; p < 0.001).
conclusionElevated GFAP and NfL were independently associated with greater sarcopenia severity, suggesting neurodegenerative involvement in sarcopenia among older Indian adults. These biomarkers may offer valuable insights into the neural contributions to muscle decline in aging populations and could support future risk stratification and early intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.